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Adenovirus E1A drives oncogenesis by targeting key regulatory
pathways that are critical for cellular growth control. The interac-
tion of E1A with p400 is essential for many E1A activities, but the
downstream target of this interaction is unknown. Here, we
present evidence that the oncoprotein transcription factor Myc is
the target of this interaction. We show that E1A stabilizes Myc
protein via p400 and promotes the coassociation of Myc and p400
at Myc target genes, leading to their transcriptional induction. We
also show that E1A requires Myc for its ability to activate Myc-
dependent gene expression and induce apoptosis, and that forced
expression of Myc is sufficient to rescue the activity of an E1A-
mutant defective in p400 binding. Together, these findings estab-
lish that Myc, via p400, is an essential downstream target of E1A.
proteolysis  transcription  transformation  apoptosis
One of the most important tools for exposing themechanismsof oncogenic transformation are DNA tumor viruses. Be-
cause these viruses, such as adenovirus, depend on the cellular
DNA replication machinery to propagate, they must drive host
cells into the cell cycle. It is this release from cellular growth
control that promotes oncogenic transformation. The utility of
DNA tumor viruses for cancer research is based on the premise
that they have evolved to target the minimum number of cellular
pathways necessary for virus propagation and cellular transfor-
mation. Understanding how DNA tumor viruses promote on-
cogenesis, therefore, can reveal the most vulnerable cellular
pathways and nodes that are linked to tumorigenesis.
Adenovirus E1A is perhaps the most widely studied oncogene
from a DNA tumor virus. E1A encodes proteins that have a range
of activities, including the ability to induce cell proliferation and
transformation, inhibit differentiation, and promote apoptosis.
E1A proteins exert these effects by binding to, and modifying the
function of, key cell cycle regulators (1). The most prominent of
these regulators is the tumor suppressor protein Rb, but interac-
tions of E1A with chromatin remodeling factors such as p300/CBP
(2) and p400 (3) also contribute to its biological activities. The
interaction of E1Awith p400 is particularly important because E1A
fails to induce apoptosis in cells that do not express p400 (4), and
an E1A mutant that is specifically defective for p400 binding
(26–35), but can still interact with p300/CBP, is impaired for both
transformation and apoptosis (3, 4). Although p400 is clearly
required for E1A’s activities, the mechanism through which it
functions in this capacity is unknown.
Recently, it was reported that E1A can inhibit the ubiquitin
(Ub)-mediated destruction of Myc during the course of adeno-
virus infection (5). It has also been reported that E1A can
interact with multiple subunits of the 19S proteasome to inhibit
proteasomal proteolysis (6). Although global proteasome inhi-
bition could account for the stabilization of Myc by E1A, the
exact mechanism through which E1A stabilizes the Myc protein
is unknown. We have investigated how E1A attenuates Myc
proteolysis and find that, contrary to expectations, stabilization
of Myc does not occur via widespread proteasome inhibition.
Instead, E1A stabilizes Myc by promoting its association with
p400, which in turn reduces Myc ubiquitylation and promotes
formation of a Myc–p400 cocomplex on promoter DNAs. Con-
sistent with these findings, we also show that E1A can activate
Myc target genes and that Myc is an essential downstream
effector of E1A. Together, these data reveal that stabilization of
Myc by E1A is a specific targeted effect of the adenoviral protein
and establish that the E1A–p400–Myc connection is important
for oncogenesis.
Results and Discussion
To examine the effects of E1A on Myc protein stability, human
U2OS cells were infected with the Ad5 adenovirus dl520, which
expresses WT 12S E1A, and endogenous Myc protein levels were
assessed by Western blot (WB; Fig. 1A). Six to 8 h after infection,
at the point at whichE1Aexpressionwas first detected, we observed
an increase in steady-state Myc levels, which gradually subsided
over a 12- to 24-h period. Consistent with previous reports (5), the
increase inMyc protein levels at 6 h was accompanied by a decrease
in the levels of Myc mRNA (Fig. 1B). Although Baluchamy et al.
(7) have reported that adenovirus activates Myc gene expression,
these experiments were done in quiescent cells; our assays, and
those of Lohr et al. (5), were performed in cycling cells, suggesting
that regulation of Myc transcription by adenovirus is influenced by
the growth status of the cells.
The transient increase in Myc levels we observed, together
with the decline in Myc mRNA, suggested that Myc is stabilized
during the course of adenovirus infection. This notion was
confirmed by treating infected cells with cyclohexamide (CHX),
and monitoring Myc levels by WB (Fig. 1C). Under these
conditions, adenovirus stabilized Myc considerably, and in a
manner that depended on E1A; a virus that expresses LacZ
(-gal) instead of E1A did not induce Myc stability (Fig. 1C).
Importantly, expression of E1A alone was sufficient to stabilize
Myc; retroviral expression of 12S E1A in U2OS cells resulted in
a potent stabilization of Myc (Fig. 1D) and a commensurate
decrease in Myc mRNA levels (Fig. 1E). Thus, confirming
earlier work (5), E1A promotes Myc stability.
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E1A has been shown to interact with multiple subunits of the
19S proteasome, and this interaction has been proposed to
inhibit proteasomal proteolysis (6). Because Myc proteolysis
requires proteasome function (8), global inhibition of protea-
some activity by E1A could account for its ability to stabilize
Myc. It is important to note, however, that E1A has not been
shown to elicit widespread proteasome inhibition in vivo. We
therefore asked whether adenoviral infection stabilizes the syn-
thetic protein U-GFP (9), a substrate that is widely used as an
in vivo reporter of proteasome activity (Fig. 1F). Under condi-
tions where adenovirus stabilized Myc, there was little, if any,
change in the rate of destruction of U-GFP, demonstrating that
proteasome function is not generally attenuated in adenovirus-
infected cells. This notion was supported by comparing the
effects of adenovirus infection and proteasome inhibition on
Myc localization [supporting information (SI) Fig. S1]. Whereas
proteasome inhibition results in the redistribution of Myc from
the nucleoplasm to the nucleolus (10), infection of cells with
adenovirus expressing E1A did not significantly alter the nuclear
distribution of the Myc protein. Thus the consequences of
stabilization of Myc by E1A are different from those of protea-
some inhibition. Taken together, these data support a model in
which the ability of E1A to stabilizeMyc does not involve general
inhibition of proteasome function.
E1A Stabilizes Myc via p400.Wenext probed for the regions of E1A
that are required to stabilize Myc. We analyzed a panel of
adenovirus E1A deletion mutants, depicted in Fig. 2A, for their
ability to stabilizeMyc at 6 h after adenovirus infection (Fig. 2B).
This experiment revealed that, of the 11 mutant viruses tested,
all but three were able to stabilize Myc efficiently. The three
viruses that failed to stabilize Myc (dl1101, dl1102, and dl1103)
encode E1A proteins with deletions that span residues 4–49.
This region of E1A is important for its interaction with p400,
CBP/p300, TBP, and Rb, but the smallest deletion that disrupts
Myc stabilization, 26–35 (dl1102), interacts with all of these
proteins, with the exception of p400 (4). Although the 26–35
mutation also disrupts interaction of E1A with the coactivator
TRRAP (11), interaction with TRRAP additionally requires
CR1; disruption of CR1 (as in the dl1104 and dl1105 viruses) did
not block the ability of E1A to stabilize Myc (Fig. 2B). Impor-
tantly, we also observed that WT E1A, but not the 26–35
mutant, stabilized Myc in Rat1 and IMR90 cells (Fig. S2),
demonstrating that the ability of E1A to interact with p400
correlates with Myc stabilization in a variety of cell types.
Together, these data indicate that adenoviral-mediated stabili-
zation of Myc requires interaction of E1A with p400.
To determine whether p400 plays a role in E1A-mediated
stabilization ofMyc, we knocked down expression of p400 in U2OS
cells by using short-hairpin-mediated gene silencing and examined
the effects of E1A onMyc turnover. This analysis (Fig. 2C) showed
that knockdown of p400 attenuates the ability of E1A to stabilize
Myc. Moreover, we found that knockdown of p400, in the absence
of E1A expression, increased the rate of Myc proteolysis and
decreased steady-state Myc protein levels (Fig. 2D), indicating that
p400 normally acts to promote Myc stability. Consistent with this
idea, overexpression of p400 promoted accumulation of Myc pro-
tein (Fig. 2E) and specifically reduced the formation of high-
molecular-weight Myc–Ub conjugates (Fig. 2F); p53–Ub conju-
gates, which we assayed as a control, were unaffected by p400
expression. Based on these results, we conclude that p400 acts to
stabilize Myc by reducing the extent of Myc ubiquitylation and that
E1A targets this process.
E1A Promotes Formation of a p400–Myc Complex. Given the ability
of p400 to stabilizeMyc, a simplemodel to explain our observations
is that E1A promotes the association of Myc and p400. To test this
model, U2OS cells expressing HA-tagged Myc and FLAG-tagged
p400 were infected with various adenoviruses, and Myc–p400
complexes were detected by coimmunoprecipitation analysis (Fig.
3A). By recovering either Myc or p400 immune complexes, we
found that WT E1A, but not the 26–35 mutant, promoted
coassociation of both proteins. Importantly, WT E1A could also
stimulate the association of Myc and p400 on promoter DNA, as
assayed by ChIP. Because commercially available anti-p400 anti-
bodies did not function for ChIP (data not shown), we expressed
FLAG-tagged p400 in cells infected with various adenoviral vectors
for these analysis. We first performed ChIP by using an antibody
against Myc and found that expression of WT E1A (encoded by
dl520), but not the 26–35 mutant (dl1101), promoted the associ-
ation ofMycwith the nucleophosmin (B23) promoter (Fig. 3B).We
then recovered Myc–DNA complexes from the ChIP reaction and
performed a second round of immunoprecipitation with anti-
FLAG antibody to recover chromatin that was bound by both Myc
Fig. 1. Adenovirus E1A stabilizes Myc. (A) U2OS cells were infected with
adenovirus dl520 and harvested at the indicated time points. Levels of Myc,
E1A, and actin were determined by WB. (B) U2OS cells were infected with
adenovirus, as in A, and RNA was harvested. Levels of c-Myc cDNAs were
analyzed by quantitative PCR and normalized to those of an actin control. (C )
U2OS cells were either infected with dl520 or a control virus expressing -gal,
mock-infected, or treated with the proteasome inhibitor, MG132, and incu-
bated for 6 h. CHX was added to inhibit protein synthesis, and protein samples
were taken at the indicated times (CT; hours). WB analysis shows the levels of
Myc, E1A, and actin. (D) U2OS cells were transduced with a retroviral expres-
sion construct encoding WT 12S E1A (pLPC E1A). CHX chase, followed by WB,
was used to analyze Myc turnover in E1A expressing cells and control (vector)
cells. (E ) RNA was isolated from cells in D, and levels of c-Myc cDNAs relative
to actin, determined by quantitative PCR. (F ) U2OS cells were transiently
transfected with a plasmid encoding unstable GFP (U-GFP) and incubated for
20 h. These cells were then either infected with dl520, mock-infected, or
treated withMG132 and incubated for 6 h. CHX chase was used to analyze the
levels of GFP, Myc, E1A, and actin.
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and p400. Consistent with the ability of E1A to promote association
of Myc and p400 in solution, expression of E1A also promoted an
enrichment of Myc–p400 cocomplexes at the B23 promoter (Fig.
3C); as expected, this enrichmentwas not observedwith the26–35
E1Amutant. The ability of E1A to promote both the association of
Myc with a target gene, and, beyond this, to promote corecruitment
of Myc and a coactivator, supports a model in which E1A func-
tionally targets Myc via its interactions with p400.
Functional Interaction Between Myc and E1A. E1A and Myc share a
number of functional similarities, including the ability to pro-
mote ectopic S-phase entry, sensitize cells to apoptosis, and
collaborate with oncogenes like Ras to transform rat fibroblasts
(12). Given our demonstration that E1A can induce both Myc
levels and the Myc–p400 interaction, we speculated that the
overlapping activities of these proteins may result, in part, from
the ability of E1A to function through Myc. To probe this idea,
we first asked whether E1A can stimulate Myc’s transcriptional
activity. We examined expression of two Myc target genes (Rcl1
and Cad) in diploid IMR90 cells transduced to express either
WT E1A or the 26–35 E1A mutant (Fig. 4A). Compared with
vector control, we found that both genes were induced by
expression of WT E1A, to a level comparable to that observed
upon overexpression of Myc. The 26–35 E1A mutant, in
contrast, failed to activate either gene. Importantly, activation of
Rcl1 (Fig. 4B) and AHCY (Fig. 4C) by E1A depended on Myc,
as siRNA-mediated knockdown of Myc in these cells attenuated
the ability of E1A to activate these genes. Similar behavior was
observed at the B23 and PCNA genes (Fig. S3). Thus E1A can
activate a Myc target gene in a Myc-dependent manner, sup-
porting the notion that it functionally stimulates theMyc protein.
The E1A–p400 interaction has recently been found to be
important for the ability of E1A to promote apoptosis (4). If, as
our model predicts, the E1A–p400 interaction functions through
Myc, we would expect that Myc will also be required for
induction of apoptosis by E1A.We therefore asked whether E1A
Fig. 2. p400 is required for E1A to stabilize Myc. (A) 12S E1A is depicted,
showing conserved regions 1 (CR1) and 2 (CR2). The positions of adenovirus
E1A deletion mutants dl1504 and dl1101–dl1110 are shown above, and
residues required for interaction with p400 are shown below. (B) U2OS cells
were infected with adenovirus deletion mutants, or dl520, and incubated for
6 h, and CHX chase was performed. WB was used to monitor levels of E1A and
endogenous Myc. (C ) U2OS cells were transduced with retroviral expression
constructs encoding (i ) a short hairpin directed against p400 (sh p400), or
vector control, and (ii ) WT 12S E1A, or vector control (). CHX chase followed
by WB analysis was used to determine levels and stability of Myc and E1A. (D)
WB analysis was used to determine levels of Myc and p400 in control () and
p400 hairpin ()-expressing cells. (E) U2OS cells were transiently transfected
with HA-tagged Myc, in the absence () or presence of an expression construct
encoding p400. Levels of Myc and p400 were determined by immunoblotting.
(F ) U2OS cells were transfected with expression vectors encoding either Myc
or p53, together with FLAG-tagged p400 (or vector control), and a plasmid
expressing His-tagged Ub (20). Ub conjugates were recovered by Ni-NTA
chromatography, and ubiquitylated Myc and p53 proteins were detected
by WB.
Fig. 3. E1A expression promotes the formation of Myc–p400 complexes. (A)
U2OS cells were transiently transfected with HA-tagged Myc and FLAG-
tagged p400 for 48 h. Transfected cells were infected for 6 h with-GAL,dl520,
or dl1102 adenovirus. Coimmunoprecitation was performed as described (4)
by using anti-Myc (N262) or anti-FLAG (M2) antibodies, and Myc and p400
were detected by WB. (B) U2OS cells were transfected with FLAG-p400 or
control DNA for 48 h and then infected with -GAL, dl520, or dl1102 adeno-
virus for 6 h. ChIP analysis was performed by using the anti-Myc antibody
N262, and coprecipitating DNAs corresponding to the B23 E-box were de-
tected by quantitative PCR. Enrichment is calculated relative to a non-Myc
binding sequence. (C ) Protein–DNA complexes recovered inBwere eluted and
subject to a second round of ChIP with anti-FLAG antibodies to recover
p400-containing chromatin. Levels of coprecipitating DNA from the B23 E-box
were determined by quantitative PCR. To control for nonspecific background,
signal in the re-ChIP was normalized to that from an identical, parallel,
experiment from cells not expressing FLAG-tagged p400.
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can induce apoptosis in Rat1 fibroblasts in which both copies of
the c-myc gene were disrupted by homologous recombination
(13). In Rat1 cells, E1A was a potent inducer of apoptosis
triggered by adriamycin (Fig. 4D; see Fig. S4A for expression
data on the E1A and Myc proteins). In congenic Myc-null cells,
however, E1A was unable to induce apoptosis. This deficit was
caused by a loss of Myc and not a secondary mutation, because
reintroduction of Myc into Myc-null cells restored the ability of
E1A to induce apoptosis. Importantly, this deficit was not caused
by a general defect in E1A activity inMyc-null cells. Our previous
studies have shown that binding of E1A to Rb is important for
inducing the expression of several caspases, and that this induc-
tion potentiates cell death in E1A-expressing cells (14).When we
examined caspase-7 levels in our system (Fig. 4E), we found that
E1A was capable of inducing caspase-7, and that this induction
was not diminished in Myc-null cells. This result demonstrates
clearly that the ability of E1A to function via the Rb pathway
does not depend onMyc expression and reveals that only a subset
of E1A activities require Myc.
A key prediction of our model is that overexpression of Myc
should rescue defects in E1A that are associated with loss of the
p400 interaction. To challenge this prediction, we asked whether
overexpression of Myc can restore the ability of the E1A 26–35
mutant to sensitize cells to apoptosis (4). As reported (15), expres-
sion of E1A in IMR90 fibroblasts sensitizes them to apoptosis in the
presence of adriamycin (Fig. 4F Left) and results in the induction of
both ARF and p53 (Fig. S4B). Under these conditions, E1A is a
more potent inducer of apoptosis than Myc, and its proapoptotic
Fig. 4. Myc is a downstream effector of E1A. (A) IMR90 cells were transduced by retroviral vectors expressing 12S E1A, the E1A 26–35 mutant, or Myc. RNA
was harvested, and levels of Rcl1 and Cad cDNAs were determined by quantitative PCR. (B) IMR90 cells were transduced with the indicated retroviruses, and then
transfected with either nontargeting siControl, or siMyc RNA, duplexes for 48 h. RNA was then harvested and levels of Rcl cDNA were analyzed by quantitative
PCR. Fold induction is normalized to an actin control for each sample. (C ) As in B but assaying for levels of AHCY cDNA. (D) WT (TGR-1 cells) or congenic myc/
Rat-1 cells (HO.15.19 cells) were transduced with retroviruses expressing, E1A, E1A26–35, or empty vector, and the resulting cell populations were treated with
adriamycin and assessed for viability after 24 h by trypan blue exclusion. The myc/; Myc panel representsmyc/ cells where full-length Myc was reintroduced
by retroviral gene transfer. (E ) WB analysis of samples derived from C showing expression of caspase-7, E1A, or tubulin. (F ) IMR90 cells were transduced with
retroviral expression constructs encoding E1A (●), E1A 26–35 (Œ), E1A CR2 (), Myc (), E1A 26–35Myc (E), E1A CR2Myc (‚), or an empty vector (f).
Cell populations were treated with the indicated doses of adriamycin for 24 h, and viability was determined by trypan blue exclusion. (G ) BJ fibroblasts were
retrovirally transduced with the indicated constructs. The resulting cells were assayed for colony formation in soft agar.
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activity (Fig. 4F), and ability to induce ARF and p53, is disrupted
by the 26–35 mutation. As predicted from the model, overex-
pression ofMyc in the presence of the26–35 E1Amutant rescued
both E1A’s ability to trigger apoptosis (Fig. 4F) and induce ARF
andp53 (Fig. S4B). The rescue ofmutantE1A functionwas specific,
because overexpression ofMyc did not rescue the apoptotic defects
of an E1A mutant (CR2) that still interacts with p400 but fails to
interact with Rb (Fig. 4F). Thus, increased expression of Myc can
specifically rescue apoptotic defects associated with loss of the
E1A–p400 interaction.
Finally, we asked whether the same phenomenon applied to the
ability of E1A to drive human cell transformation. Our previous
studies have shown that expression of E1A and activated Ha-
RasV12 in early passage normal human foreskin fibroblasts (des-
ignated BJ) allows the formation of colonies in soft agar (Fig. 4G
and ref. 16). Blocking the ability of E1A to interact with p400 also
attenuates its ability to collaborate with Ras to drive human cell
transformation in this assay (Fig. 4G). Importantly, this activity can
be restored by overexpression of Myc. Thus, overexpression of Myc
can rescue both the transformation and apoptotic defects that result
when the ability of E1A to interact with p400 is blocked. These data
are consistent with the idea that the critical function of the
E1A–p400 interaction in transformation and apoptosis is to in-
duce Myc.
Conclusions
Together, our data support a model in which the binding of E1A to
p400 promotes the formation of aMyc–p400 complex atMyc-target
gene promoters. The increase in interaction of Myc and p400 is
associated with stabilization of theMyc protein and an induction of
Myc target genes. These functions of E1A are required for its ability
to induce the ARF/p53 pathway, promote apoptosis, and drive
cellular transformation, revealing that the downstream arm of the
E1A–p400 interaction is mediated via Myc. Although it has long
been known that E2F functions as the downstream target of the
E1A–Rb interaction, the molecular processes downstream of the
E1A–p400 connection have remained obscure. Our data indicate
that Myc is the ultimate target of this connection. This finding not
only provides an explanation for the overlapping biological func-
tions of Myc and E1A, but also reveals an interesting viral strategy
for promoting oncogenesis. By targeting and activating both the
E2F and Myc transcriptional networks, E1A can provoke a syner-
gistic response in parallel pathways to efficiently couple cell cycle
progression, transformation, and apoptosis. Moreover, given that
E1A targets cellular pathways relevant to transformation, our data
also support an important role for the Myc–p400 connection in
human cancer.
Methods
Antibodies.The antibodies used in this study were: anti ()-Ad5 E1A antibodies
M73 and M58 (17) and sc-430 (Santa Cruz); -p400 monoclonal antibody
RW144 (2); -caspase-7 (14); -Myc 9E10 (Oncogene) and N262 (Santa Cruz);
-Actin AC-15 (Sigma); -GFP PC408 (Novagen); -FLAG M2 (Sigma); -p53
CM1 (Novocastra); -ARF sc-8340 (Santa Cruz); -HA 12CA5 (Roche); -tubulin
B512 (Sigma); and -nucleolin (Santa Cruz).
Cells andAdenoviruses.U2OS, IMR90,HEK293,HO.15.19,andTGR-1 (13) cellsand
BJ human fibroblasts were grown under standard conditions. WT adenovirus 5
(Ad5),dl520, was obtained from ATCC. Ad5 mutants were obtained from Arnold
Berk (University of California, Los Angeles) (18) and Philip Branton (McGill Uni-
versity, Quebec, Canada) (19). Adenoviruses were propagated in 293 cells and
purified by CsCl equilibrium centrifugation. For adenoviral infections, U2OS cells
were incubatedwithvirusatamultiplicityof infectionof15plaque-formingunits
per cell, for 1 h at 37°C with intermittent rocking.
Protein Assays. Myc protein turnover was measured by adding CHX (100
g/ml) to cells, collecting protein samples at the indicated time points, and
assaying relevant protein levels by WB. Myc and p53 conjugates were detected
by using the His-tagged Ub method after transfection of U2OS cells with
pMT107 (20), pCGN-Myc (8), pCGN-p53 (unpublished work), and pCMV-p400
(3) as indicated.
cDNAmeasurement.Where appropriate, total cellular RNA was harvested with
TRIzol (Invitrogen) and reverse-transcribed with the TaqMan kit (Applied
Biosystems), and cDNA levels from the indicated genes were quantified by
using the SYBR Green PCR Master Mix (Applied Biosystems) in conjunction
with a MJ Research CFD-3240 Chromo 4 Detector. Transcript levels for target
genes were normalized to those of actin. Primer sequences are available on
request.
RNAi. Duplex pools of siGenome RNA against Myc and nontargetting control
sequences (Dharmacon) were transiently transfected into IMR90 cells via
Oligofectamine (Invitrogen). Knockdown of Myc RNA was at least 50% (data
not shown).
Cell Viability. To assay the ability of Myc to rescue the apoptotic defect of the
E1A 26–35 mutant, IMR90 cells were stably transduced with pLPC, pLPC E1A
(21), pLPC E1A 26–35 (4), pLPC CR2 (4), or pBabe Hygro HAM Myc (22) by
retroviral infection. The resulting cell lines were plated into 12-well dishes at
a density of 1 105 cells per well. Twenty-four hours later, cells were treated
with adriamycin for 24 h. Adherent and nonadherent cells were then pooled
and analyzed for viability by trypan blue exclusion. At least 200 cells were
counted for each data point. To assay the ability of E1A to induce apoptosis in
Myc/ cells, HO.15.19, and parental Rat1 cells, TGR-1 (13) were transduced
with retroviral expression constructs for E1A, E1A 26–35, or Myc, in the
indicated combinations. Relative apoptosis was determined by comparing cell
death 24 h after treatment with increasing doses of adriamycin. Data pre-
sented are the average of three independent experiments.
Anchorage-Independent Growth. BJ normal human primary foreskin fibroblasts
were stably transduced with pBABE-Puro Ha-RasV12, pWZL-Neo E1A, or Hygro-
MarXII-Myc intheindicatedcombinationsbyretroviral infectionandanalyzedfor
anchorage-independent growth in semisolid media as described (16).
ChIP andRe-ChIPAnalysis.ChIP analyses were performed in U2OS cells that had
been transfected with either control (pUC119) or pCMV-FLAG-p400 construct
by using Fugene 6 (Roche). After 48 h, cells were infected with control, dl520,
and dl1102 adenovirus for 8 h. Primary immunoprecipitation was performed
by using anti-Myc (N262) antibody; for re-ChIP, a secondary immunoprecipi-
tation using anti-FLAG (M2) antibody was performed. Coprecipitating DNAs
after each round were assayed by quantitative PCR using either the B23C
(specific) and B23M (nonspecific control) amplicons (23). Re-ChIP DNA signals
for FLAG-p400 were further normalized to those from cells transfected with
the vector control.
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